Gary A. Eastwick, MD | Cooper ...

Dr. Gary Eastwick

Claim this profile

Cooper Hospital University Medical Center

Studies Prostate Adenocarcinoma
Studies Prostate Cancer
6 reported clinical trials
24 drugs studied

Affiliated Hospitals

Image of trial facility.

Cooper Hospital University Medical Center

Image of trial facility.

MD Anderson Cancer Center At Cooper-Voorhees

Clinical Trials Gary Eastwick is currently running

Image of trial facility.

Apalutamide + Hormone and Radiation Therapies

for Prostate Cancer

This phase III trial studies whether adding apalutamide to the usual treatment improves outcome in patients with lymph node positive prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tumors. Androgens, or male sex hormones, can cause the growth of prostate cancer cells. Drugs, such as apalutamide, may help stop or reduce the growth of prostate cancer cell growth by blocking the attachment of androgen to its receptors on cancer cells, a mechanism similar to stopping the entrance of a key into its lock. Adding apalutamide to the usual hormone therapy and radiation therapy after surgery may stabilize prostate cancer and prevent it from spreading and extend time without disease spreading compared to the usual approach.

Recruiting

2 awards

Phase 3

Image of trial facility.

Apalutamide + Targeted Radiation

for Prostate Cancer

This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation therapy and short term androgen deprivation) is more effective compared to standard of care alone in patients with prostate cancer who experience biochemical recurrence (a rise in the blood level of prostate specific antigen \[PSA\] after surgical removal of the prostate cancer). A second question tests treatment in patients with biochemical recurrence who show prostate cancer spreading outside the pelvis (metastasis) by positron emission tomography (PET) imaging. In these patients, the benefit of adding metastasis-directed radiation to enhanced therapy (apalutamide in combination with abiraterone + prednisone) is tested. Diagnostic procedures, such as PET, may help doctors look for cancer that has spread to the pelvis. Androgens are hormones that may cause the growth of prostate cancer cells. Apalutamide may help fight prostate cancer by blocking the use of androgens by the tumor cells. Metastasis-directed targeted radiation therapy uses high energy rays to kill tumor cells and shrink tumors that have spread. This trial may help doctors determine if using PET results to deliver more tailored treatment (i.e., adding apalutamide, with or without targeted radiation therapy, to standard of care treatment) works better than standard of care treatment alone in patients with biochemical recurrence of prostate cancer.

Recruiting

2 awards

Phase 3

More about Gary Eastwick

Clinical Trial Related

5 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 5 Active Clinical Trials

Treatments Gary Eastwick has experience with

  • Apalutamide
  • Radiation Therapy
  • Bicalutamide
  • Buserelin
  • Degarelix
  • Flutamide

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Gary Eastwick specialize in?

Is Gary Eastwick currently recruiting for clinical trials?

Are there any treatments that Gary Eastwick has studied deeply?

What is the best way to schedule an appointment with Gary Eastwick?

What is the office address of Gary Eastwick?

Is there any support for travel costs?